The suit has been filed in the U.S. District Court for the District of Columbia against Cephalon. According to the Commission, Cephalon, faced with threat to its Provigil monopoly, paid more than $200 million to generic drug companies to abandon their patent challenges and forgo entry into the market until April 2012. As Cephalon's CEO allegedly put it shortly after entering these settlements: "We were able to get six more years of patent protection. That's $4 billion in sales no one expected".
The FTC is clearly taking the issue very seriously, see also here.
-
TechLore, here .
-
A. Cooper et al., here.
-
The Verge, here. [BTW, while "Free the app stores" was the topic of Episode 1 of the DMA Vox Populi Podcast , Episode 2 is all ...
-
R. Podszun et mult. al., here. Differently put, they're a joke.
-
JS Tan et al., here.
-
DMA Vox Populi Podcast, here and here. Amuse bouche here. A place where we listen to essential, albeit underrepresented voices.
No comments:
Post a Comment